Perrigo announced it has received final approval from the Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Solution, the generic version of Mallinckrodt’s Pennsaid.
Diclofenac Sodium is a nonsteroidal anti-inflammatory drug (benzeneacetic acid derivative) indicated for the treatment of sign/symptoms of osteoarthritis of the knee(s). Diclofenac inhibits the enzyme, cyclooxygenase (COX), an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins, thromboxanes and prostacylin.
Diclofenac Sodium Topical Solution is available as a 1.5% 2/2 strength. Shipments of this product have begun.
For more information call (866) 634-9120 or visit Perrigo.com.